Psychiatr. pro Praxi, 2006; 6: 276-280

The Introduction to the Biological Treatment of Resistant Depression

MUDr. Martin Bareš1, MUDr. Miloslav Kopeček Ph.D1,2
1 Psychiatrické centrum Praha, 3. LF UK, Praha
2 3. LF UK, Praha

Depressive disorder is relatively common disease in population. Lifetime prevalence of major depression is 5–12% in men and 9–26% in women. Approximately 30% of patients treated with first antidepressants achieve remission. The resistant depression is commonly defined as depression which was unsuccessfully treated by 2 antidepressants from various groups. The authors comment possibilities of resistant depression treatment (change of antidepressants, augmentation and combination of antidepressants, repetitive transcranial magnetic stimulation, electroconvulsive therapy etc.).

Keywords: resistant depressive disorder, definition, treatment

Published: February 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bareš M, Kopeček M. The Introduction to the Biological Treatment of Resistant Depression. Psychiatr. praxi. 2006;7(6):276-280.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Abraham G, Milev R, Stuart Lawson J.T3 augmentation of SSRI resistant depression. J Affect Disord 2006; 91: 211 - 215. Go to original source... Go to PubMed...
    2. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (Revision). Am J Psychiatry 2000; 157 (Suppl.).
    3. Anderson IM, Nutt DJ, Deakin JF. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology. J Psychopharmacol 2000; 14: 3-20. Go to PubMed...
    4. Appelberg BG, Syvalahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukarinen HH. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: Results from a placebo-controlled, randomized, double blind, placebo wash- in study. J Clin Psychiatry 2001; 62: 448-452. Go to original source... Go to PubMed...
    5. Aronson R., Offman HJ, Joffe RT, Naylor CD. Triiodthyronine augmentation in the treatment of refractory depression: a meta - analysis. Arch Gen Psychiatry 1996; 53: 842-848. Go to original source... Go to PubMed...
    6. Baldomero EB, Ubago JG, Cercos CL, Ruiloba JV, Calvo CG, Lopez RP.Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study. Depress Anxiety. 2005; 22: 68-76. Go to original source... Go to PubMed...
    7. Bareš M, Brunovský M, Kopeček M, Stopková P, Novák T, Vonásková K, Kožený J. Changes in QEEG prefrontal cordance as a predictor of response to antidepressants in patients with treatment resistant depressive disorder: a pilot study. J Psych Res 2006. In press.
    8. Bareš M, Hrdlička M, Propper L, Borzová K. Elektrokonvulzivní léčba v pokračovací a udržovací léčbě poruch nálady. Čes a Slov Psychiat 1999; 95: 212-219.
    9. Bareš M, Kopeček M. Repetitivní transkraniální magnetická stimulace (rTMS) a deprese. Psychiatrie 2005; (Suppl 3): 69-80.
    10. Bareš M, Mohr P, Hendrychová Y, Kopeček M. Vagová stimulace (VNS) v léčbě rezistentní depresivní poruchy - 1. rok zkušeností. Kasuistika. Psychiatrie 2006; 10: 1-3.
    11. Bauer M, Adli M, Baethge C, Berghofer A, Sasse J, Heinz A, Bschor T. Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms. Can J Psychiatry 2003; 48: 440-448. Go to original source... Go to PubMed...
    12. Brown WA, Harrison W. Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? J Clin Psychiatry 1995: 56: 30-34.
    13. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 2002; 51: 183-188. Go to original source... Go to PubMed...
    14. Cook IA, Leuchter AF, Morgan ML, Stubbeman W, Siegman B, Abrams M. Changes in prefrontal activity characterize clinical response in SSRI nonresponders: a pilot study. J Psych Res 2005; 39: 461-466. Go to original source... Go to PubMed...
    15. Corya SA, Williamson D, Sanger TM, Briggs SD, Case M, Tollefson G. A randomized, doubleblind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety. 2006 May 18; [Epub ahead of print]. Go to original source... Go to PubMed...
    16. David MM, Owen JA, Abraham G, Delva NJ, Southmayd SE, Wooltorton E, Lawson JS. Thyroid function and response to 48-hour sleep deprivation in treatment-resistant depressed patients. Biol Psychiatry 2000; 48: 323-336. Go to original source... Go to PubMed...
    17. Fava M, Alpert J, Nierenberg A, Lagomasino I, Sonawalla S, Tedlow J, Worthington J, Baer L, Rosenbaum JF. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol 2002; 22: 379-387. Go to original source... Go to PubMed...
    18. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003; 53: 649-659. Go to original source... Go to PubMed...
    19. Fava M. New approaches to the treatment of refractory depression. J Clin Psychiatry 2000; 61(Suppl. 1): 26-32.
    20. George MS, Rush JA, Marangell LB, Sackeim HA, Brannan SK, Davis SM et al. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry 2005; 58: 364-373. Go to original source... Go to PubMed...
    21. Joffe RT, Levitt AJ, Sokolov STH, Young LT. Response to an open trial of a second SSRI in major depression. J Clin Psychiatry 1996; 57: 114-115.
    22. Kielholz P, Tarzani S, Gastpar M, Adams C. Zur behandlung therapieresistenter depressionen. Ergebnisse einer kombinierten infusionstherapie. Schweiz Med Wochenschr 1982; 112: 1090-1095. Go to PubMed...
    23. Lam RW, Wan DDC, Cohen NL, Kennedy SH. Combining antidepressants for treatment - resistant depression: a review. J Clin Psychiatry 2002; 63: 685-693. Go to original source... Go to PubMed...
    24. Landen M, Bjorling G, Agren H, Fahlen T. A randomized double blind, placebo - controlled trial of buspirone with an SSRI in patients with treatment resistant depression. J Clin Psychiatry 1998; 59: 664-668. Go to original source... Go to PubMed...
    25. Licht RW, Quitzau S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment: a randomized study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology 2002; 161: 143-151. Go to original source... Go to PubMed...
    26. Nelson JC, Mazure CM, Jatlow PI, Bowers MB Jr.,Price LH. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry 2004; 5: 296-300. Go to original source... Go to PubMed...
    27. Nierenberg AA, Amsterdam JD. Treatment-resistant depression: definition and treatment approaches. J Clin Psychiatry 1990; 51: 39-47.
    28. O'Reardon JP, Blumner KH, Peshek AD, Pradilla RR, Pimiento PC. Long-term maintenance therapy for major depressive disorder with rTMS. J Clin Psychiatry 2005; 66: 1524-1528. Go to original source... Go to PubMed...
    29. Perez V, Soler J, Puigdemont D, Alvarez E, Artigas F. A double-blind, randomized, placebocontrolled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius. Arch Gen Psychiatry 1999; 56: 375-379. Go to original source... Go to PubMed...
    30. Poirer MF, Boyer P. Venlafaxine and paroxetine in treatment - resistant depression: doubleblind randomized comparison. Br J Psychiatry 1999; 175: 12-16. Go to original source... Go to PubMed...
    31. Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. J Clin Psych 2005; 66: 148-158. Go to original source... Go to PubMed...
    32. Prudic J, Haskett RF, Mulsant B, Malone KM, Pettinati HM, Stephens S, Greenberg R, Rifas SL, Sackeim HA. Resistance to antidepressant medications and short term clinical response to ECT. Am J Psychiatry 1996; 153: 985-992. Go to original source... Go to PubMed...
    33. Prudic J, Sackeim HA, Devanand DP. Medication resistance and clinical response to electroconvulsive therapy. Psychiatry Res 1990; 31: 287-296. Go to original source... Go to PubMed...
    34. Rush AJ, Marangell LB, Sackeim HA, George MS, Brannan SK, Davis SM et al. Vagus nerve stimulation for treatment - resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005; 58: 347-354. Go to original source... Go to PubMed...
    35. Rush AJ, Sackeim HA, Marangell LB, George MS, Brannan SK, Davis SM et al. Effects of 12 months of vagus nerve stimulation in treatment - resistant depression. Biol Psychiatry 2005; 58: 355-363. Go to original source... Go to PubMed...
    36. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, Ritz L, Biggs MM, Warden D, Luther JF, Shores-Wilson K, Niederehe G, Fava M. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006; 354: 1231-1242. Go to original source... Go to PubMed...
    37. Rush JA, Fava M, Wisniewski SR et al. Sequenced Treatment Alternatives to Relieve Depression (STAR*D): rationale and design. Control Clin Trials 2004; 25: 119-142. Go to original source... Go to PubMed...
    38. Rush JA, Thase ME, Dube S. Research issues in the study of difficult-to-treat depression. Biol Psychiatry 2003; 53: 743-753. Go to original source... Go to PubMed...
    39. Sackeim HA, Haskett RF, Mulsant BH, Thase ME, Mann JJ, Pettinati HM, Greenberg RM, Crowe RR, Cooper TB, Prudic J. Continuation Pharmacotherapy in the Prevention of Relapse Following Electroconvulsive Therapy. A Randomized Controlled Trial. JAMA 2001; 285: 1299-1307. Go to original source... Go to PubMed...
    40. Sackeim HA. The definition and meaning of treatment - resistant depression. J Clin Psychiatry 2001; 62 (Suppl. 16): 10-17.
    41. Seifertová D, Bareš M, Kopeček M. Antipsychotika v léčbě farmakorezistentní deprese. Psychiatr. pro Praxi 2006; 3: 122-125.
    42. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA, Feldman PD, Meltzer HY. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158: 131-134. Go to original source... Go to PubMed...
    43. Souery D, Amsterdam J, de Montigny C, Lecrubier Y, Montgomery S, Lipp O, Racagni G, Zohar J, Mendlewicz J. Treatment resistant depression. Methodological overview and operational criteria. Eur Neuropsychopharmacol 1999; 9: 83-91. Go to original source... Go to PubMed...
    44. Thase M, Kremer C, Rodrigues H. Mirtazapine versus sertraline after SSRI non-response. European Neuropsychopharmacology 2001; 11 (Supplement 3): S342. Go to original source...
    45. Thase ME, Blomgren SL, Birkett MA, Apter JT, Tepner RG. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 1997; 58: 16-21. Go to original source... Go to PubMed...
    46. Thase ME, Rush AJ. Treatment - resistant depression. In. Bloom FE, Kupfer Dj (eds), Psychopharmacology: The Fourth Generation of Progress. Raven Press Ltd. 1995, New York: 1081-1098.
    47. Thase ME, Shelton RC, Khan A. Treatment of SSRI nonresponders with venlafaxine extended release: a randomized comparison of standard and higher dosing strategies. J Clin Psychopharmacol 2006; 26: 250-258. Go to original source... Go to PubMed...
    48. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz BD, Biggs MM, Luther JF, Shores-Wilson K, Rush AJ.Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006; 354: 1243-1252. Go to original source... Go to PubMed...
    49. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L. et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163: 28-40. Go to original source... Go to PubMed...
    50. Zarate CA, Kando JC, Tohen M et al. Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? J Clin Psychiatry 1996; 57: 67-71.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.